

**Press release****3 November 2017**

Nuevolution appoints Johnny Stilou as Director of Investor Relations and Corporate Communication

Stockholm, 3 November 2017 – Nuevolution AB (publ) (NUE.ST) today announced the appointment of Johnny Stilou as Director of Investor Relations & Corporate Communication. This is a new position within the company, which has been established to further support a successful execution of the company's goals including the continuous ambition of strengthening the shareholder base with international and institutional investors, but also and not the least to ensure that Nuevolution keep close bonds with its shareholders, and maintain high quality communication to the market. Johnny Stilou will join the company as early as possible during the first quarter 2018, but no later than 1 March 2018. Johnny will become member of the management team with reference to the CEO.

Johnny Stilou, 50 years, has significant experience with investor relations work as well as corporate communication from Veloxis Pharmaceuticals (publicly listed on Nasdaq Copenhagen main market) during the period 2008-2016, where he was the CFO, and was responsible for all investor relations work both in the US and EU. Johnny is currently CFO at the Fritz Schur Technical Group. He has an MSc in Business Economics and Auditing from Copenhagen Business School.

“Although I have appreciated my job at Fritz Schur during the last 15 months, I really wanted to come back to the dynamic biotech industry. I see Nuevolution as an ambitious company in the process of executing a very exciting strategy that I could not resist becoming part of. I am looking forward to joining the company and its strong team”, said Johnny Stilou.

“We are very fortunate to have someone of Johnny's calibre and experience join our company in this important role. With the ambition to become a main market company, and in consideration of the ambitious goals we have, I am very glad that we may soon further strengthen our good team with Johnny's strong experience within investor relations and corporate communication”, said Alex Gouliaev, CEO.

For more information, please contact:

Alex Gouliaev, CEO

Tel.: +45 2725 1402

Email: ahg@nuevolution.com

Henrik Simonsen, CFO

Tel.: +45 3913 0947

Email: hs@nuevolution.com

**Information about Nuevolution AB (publ)**

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution's internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

The information was sent for publication, through the agency of the contact persons set out above, on Friday 3 November 2017 at 12:30 CET.

Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com.

